Kalaris Therapeutics News and Activities
Presence
Headquarters: United States (USA)
Kalaris Therapeutics is a company listed under the stock ticker KLRS (US).
Acquisition, funding and merger involving Kalaris Therapeutics.
- AlloVir and Kalaris Therapeutics have announced they will merge (posted on March 24 2025)..
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Kalaris Therapeutics
- Andrew Oxtoby, President and Chief Executive Officer
- Napoleone Ferrara, Director
- Morana Jovan-Embiricos, Director
Popular executive movements at Kalaris Therapeutics
- Matthew Gall, Chief Financial Officer, has left the company (posted on April 16 2026).
- Matthew Gall has joined the company as Chief Financial Officer (posted on November 4 2025).
Create your alert
to follow the executive moves at Kalaris Therapeutics.
Biotechnology
Kalaris Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
Popular contacts in Biotechnology
News
Press releases by Kalaris Therapeutics
- Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD | Wed, 12/17/2025 - 16:01
- Kalaris Therapeutics – Your vision, our mission
- Kalaris and AlloVir Announce Stockholder Approval of Merger
- AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
Social media about Kalaris Therapeutics
- Kalaris Therapeutics on Wikipedia, Google News & Yahoo Finance
- Kalaris Therapeutics on LinkedIn, X (Twitter) & YouTube
